Health Canada Approves Lecanemab: A Breakthrough in Alzheimer’s Treatment? | What You Need to Know

Health Canada has approved lecanemab (Leqembi), the first disease-modifying drug for Alzheimer’s disease. This groundbreaking treatment slows disease progression in early-stage patients but comes with high costs, potential side effects, and accessibility concerns. In this video, we break down:
How lecanemab works to target beta-amyloid plaques
The risks of microbleeds and brain swelling
Why it’s not suitable for patients with two copies of the APOE e4 gene
The cost of treatment and MRI monitoring requirements
What this approval means for Alzheimer’s patients in Canada
Expert opinions from researchers and advocacy groups
If you or a loved one is affected by Alzheimer’s, this video provides essential insights into this new treatment option. Don’t forget to like, share, and subscribe for more updates on medical breakthroughs!